TWST Stock — Twist Bioscience Corp

Up next

Next earnings call

Nov 2, 2026 Est · unconfirmed · in 4 wks

Latest filing: 10-Q

filed Aug 3, 2026

Q3 2026 earnings call transcript

call held Aug 3, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$431.80M

Trailing 12 months

Net income (TTM)

−$136.72M

Trailing 12 months

Revenue growth YoY

+23.2%

Year over year

Operating margin

-33.6%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-0.8%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+2.0%

Year over year · more shares

Price change (1Y)

+515.0%

Trailing year

Short interest

19.9%

Latest settlement · 8.9 days to cover

View all 115 metrics

AI Brief

Q3 FY26 earnings call · Aug 3, 2026

Q3 FY26

TL;DR. Twist Bioscience reported record Q3 revenue of $118.4 million (up 23% YoY), raised full-year FY26 revenue guidance by $12M at the midpoint to $456–457M, and reiterated Q4 adjusted EBITDA breakeven, while expressing confidence in triple-digit order growth for AI-enabled drug discovery in FY27.

Bullish

+ Reported record Q3 revenue of $118.4M, up 23% YoY, marking the 14th consecutive quarter of sequential growth.
+ Raised FY26 total revenue guidance by $12M at the midpoint to $456–457M (~21% YoY growth).
+ Gross margin expanded 120 bps sequentially to 52.8%, with management targeting >52% for FY26 and >60% as the business matures.
+ DSPS revenue grew 39% YoY to $56.6M, driven by therapeutics revenue up 49% YoY to $40.4M, including strength in AI-enabled drug discovery.
+ Expects to meet or exceed triple-digit percentage AI-enabled drug discovery order growth in FY26 and to again deliver triple-digit growth in FY27 orders.
+ Reiterated expectation of Q4 FY26 adjusted EBITDA breakeven, with one-time Q3 employee transition costs expected to reduce Q4 OpEx by more than $5M.

Bearish

− Q3 GAAP net loss widened to $35.1M ($0.56/share) versus prior-year net income of $20.4M, which had benefited from a $48.8M Atlas Data Storage gain.
− Industry and applied revenue declined 7% YoY to $5.7M from $6.1M.
− Cash, cash equivalents and short-term investments declined to $166.8M at quarter-end from $171.7M as of March 31, 2026.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Bearish Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +145%

above

Price vs 50-day avg +39%

above

RSI (14) 71

overbought

MACD trend Positive

52-week position 97%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +47%

trailing

6-month return +274%

trailing

YTD return +495%

this year

Relative strength +262%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $136 › 200d $77 — 50d above 200d

Institutional flow Distributing

1 of 339 funds reported for Sep 30 · net -6 sh shares

Insider flow Distributing

Net -$4.8M over 90 days · 100% sells

Short interest Rising

19.94% of float · ▲ +3.6% MoM · 8.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

339 holders — near 3-yr high, broad support

Squeeze score 92

high risk · 0–100

Fundamentals

Strong

Revenue growth +20%

Y/Y

EPS growth +64%

Y/Y

Free cash flow $-75.6M

Balance sheet $89.5M

net cash

Quant / Vol

risk profile

Very High

Volatility 77%

annualized · 1-yr

Max drawdown −26%

past year

ATR 6.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 8 of last 8

Latest guidance · from the 8-K filed Aug 3, 2026

full fiscal year 2026

Total revenue Initiated $456M – $457M

prior FY $376.57M midpoint +21.2% Y/Y

Gross margin Initiated at least 52%

fourth quarter

Total revenue $123M – $124M

prior qtr $118.38M midpoint +4.3% QoQ

Guided vs delivered · last 8 settled

Total revenue fiscal year 2024

guided $310M – $311M

guided $310M – $311M $312.97M Beat +0.8%

Total revenue fourth quarter of fiscal year 2024

guided $82M – $83M

guided $82M – $83M $84.71M Beat +2.7%

Total revenue third quarter of fiscal year 2024

guided $77M

guided $77M $81.46M Beat +5.8%

Total revenue second quarter of fiscal year 2024

guided $70M – $71M

guided $70M – $71M $75.3M Beat +6.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+145% Bullish

Price vs 50-day avg

+39% Bullish

RSI (14)

71 Bearish

MACD trend

Positive Bullish

52-week position

97% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $136 › 200d $77 — 50d above 200d

Institutional flow Distributing

1 of 339 funds reported for Sep 30 · net -6 sh shares

Insider flow Distributing

Net -$4.8M over 90 days · 100% sells

Short interest Rising

19.94% of float · ▲ +3.6% MoM · 8.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

339 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $25 Now $189 · 97% Range high $193

vs 200-day avg +145% vs 50-day avg +39%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TWST Twist Bioscience Corp this stock	$11.46B	+494.8%	+20.3%	—	19.9%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+544.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

339

% held: 122.7%
Reported: 1 of 339
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

364

View

Short & Settlement

Short Interest Rising

Shares short

12.5M

Days to cover: 8.9d
Change: +439.9K sh

View

Short Volume

Short vol %

34%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

1.0K

Value: $130.8K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

49.1%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$4.8M

Buyers / Sellers: 0 / 7

Buyers Sellers

View

Congressional Trades Sell

Member

Dwight Evans

Amount: $1.0K–$15.0K
Traded: Mar 30, 2022

View

Financials

Net income (FY)

$-77.7M

EPS diluted: $-1.30

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 15, 2026
This year: 19

View

Proposed Sales

Value

$1.9M

Shares: 10.1K
Filed: Oct 2, 2026

View

Earnings & Events

Webcasts

Last webcast

Sep 15, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
TWST	+3.2%	+46.6%	+274.5%	-2.4%	+494.8%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	+3.4%	+47.1%	+262.3%	-3.3%	+481.9%

TWST · Twist Bioscience Corp

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance